Clinical Focus

Previous Articles     Next Articles

Clinical effect of  Danshen Chuanxiongqin combined with Nimodipine in treatment of transient ischemic attack

  

  1. 1.Department of  Medicine, Hubei Provincial Women and Children Hospital,
    Wuhan 430070, China; 2.Department of Neurology, Wuhan Union Hospital, Wuhan 430022, China
  • Online:2016-12-05 Published:2016-12-01
  • Contact: Corresponding author: Wang Xiaojun, Email:wangxiaojun62@aliyun.com

Abstract: ObjectiveTo explore the clinical effect of Danshen Chuanxiongqin combined with Nimodipine in treatment of transient ischemic attack (TIA).MethodsA total of 100 cases of TIA were selected and randomly divided into control (B) and treatment(A) groups. The patients in group B received Danshen Chuanxiongqin with aspirin, and those in group A got Danshen Chuanxiongqin combined with Nimodipine, and aspirin. The levels of blood pressure, blood plasma homocysteine (Hcy), platelet aggregation (PAG) and pulse index (PI) and resistant index (RI) of related arteries (such as common carotid artery, internal carotid artery, internal vertebra artery, external vertebra artery) were measured before and after treatment. And 50 healthy volunteers served as blank control group. All data were processed by SPSS 16.0. ResultsThe levels of blood pressure, PAG and PI and RI of related arteries were obviously different before and 3 weeks′ after treatment in group B and group A than in blank control group(P<0.05).Compared with pretreatment, the level of Hcy was greatly decreased after treatment in group A(P<0.05),and there was no statistic significant difference before and after treatment in group B(P>0.05). There were few side effects in two groups. ConclusionThe therapy of Danshen Chuanxiongqin combined with Nimodipine can significantly improve hemodynamics and hemorheology of related arteries, and reduce the levels of blood pressure and Hcy. Meanwhile, the therapy is safe and  may play an important role in preventing brain stroke.

Key words: ischemic attack, transient, tetramethylpyrazine, nimodipine